134 related articles for article (PubMed ID: 1982759)
21. The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.
Nattel S; Gagne G; Pineau M
Clin Pharmacokinet; 1987 Nov; 13(5):293-316. PubMed ID: 2891461
[TBL] [Abstract][Full Text] [Related]
22. Drug-drug interactions of beta-adrenoceptor blockers.
Brodde OE; Kroemer HK
Arzneimittelforschung; 2003; 53(12):814-22. PubMed ID: 14732961
[TBL] [Abstract][Full Text] [Related]
23. Prediction of metabolic drug interactions involving beta-adrenoceptor blocking drugs.
Park BK
Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):3S-10S. PubMed ID: 6146338
[TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.
Riddell JG; Harron DW; Shanks RG
Clin Pharmacokinet; 1987 May; 12(5):305-20. PubMed ID: 2886244
[TBL] [Abstract][Full Text] [Related]
25. Comparative beta-adrenoceptor blocking effects of propranolol, bisoprolol, atenolol, acebutolol and diacetolol on the human isolated bronchus.
Naline E; Sarria B; Ertzbischoff O; Ozanne P; Advenier C
Br J Clin Pharmacol; 1990 Jul; 30(1):135-9. PubMed ID: 1975197
[TBL] [Abstract][Full Text] [Related]
26. Beta-adrenoceptor-blocking agents: pharmacokinetic differences and their clinical implications illustrated on pindolol.
Meier J
Cardiology; 1979; 64 Suppl 1():1-13. PubMed ID: 42483
[No Abstract] [Full Text] [Related]
27. Single-dose kinetics of oral propranolol, metoprolol, atenolol, and sotalol: relation to lipophilicity.
Ochs HR; Greenblatt DJ; Arendt RM; Schäfer-Korting M; Mutschler E
Arzneimittelforschung; 1985; 35(10):1580-2. PubMed ID: 2866772
[TBL] [Abstract][Full Text] [Related]
28. Altered pharmacokinetics of beta-adrenoceptor blocking drugs in patients with renal insufficiency.
Tjandramaga TB
Arch Int Pharmacodyn Ther; 1980; Suppl():38-53. PubMed ID: 6106457
[TBL] [Abstract][Full Text] [Related]
29. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.
Bouchard J; Shepherd G; Hoffman RS; Gosselin S; Roberts DM; Li Y; Nolin TD; Lavergne V; Ghannoum M;
Crit Care; 2021 Jun; 25(1):201. PubMed ID: 34112223
[TBL] [Abstract][Full Text] [Related]
30. The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol.
Jack DB; Kendall MJ; Dean S; Laugher SJ; Zaman R; Tenneson ME
Biopharm Drug Dispos; 1982; 3(1):47-54. PubMed ID: 6123352
[TBL] [Abstract][Full Text] [Related]
31. [Antibiotic use in patients with renal or hepatic failure].
Ramón Azanza J; García E; Sádaba B; Manubens A
Enferm Infecc Microbiol Clin; 2009 Dec; 27(10):593-9. PubMed ID: 19853975
[TBL] [Abstract][Full Text] [Related]
32. The pharmacokinetics of the enantiomers of atenolol.
Boyd RA; Chin SK; Don-Pedro O; Williams RL; Giacomini KM
Clin Pharmacol Ther; 1989 Apr; 45(4):403-10. PubMed ID: 2702798
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of acebutolol and its main metabolite, diacetolol after oral administration of acebutolol in rabbits with carbon tetrachloride-induced hepatic failure.
Choi JS; Burm JP
Arch Pharm Res; 2002 Aug; 25(4):541-5. PubMed ID: 12214869
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol.
Flouvat B; Roux A; Chau NP; Viallet M; Andre-Fouet X; Woehrle R; Gregoire J
Eur J Clin Pharmacol; 1981 Mar; 19(4):287-92. PubMed ID: 7286031
[TBL] [Abstract][Full Text] [Related]
35. Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.
Frishman WH; Alwarshetty M
Clin Pharmacokinet; 2002; 41(7):505-16. PubMed ID: 12083978
[TBL] [Abstract][Full Text] [Related]
36. Stereoselective renal clearance of pindolol in humans.
Hsyu PH; Giacomini KM
J Clin Invest; 1985 Nov; 76(5):1720-6. PubMed ID: 4056049
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology.
Ågesen FN; Weeke PE; Tfelt-Hansen P; Tfelt-Hansen J;
Pharmacol Res Perspect; 2019 Aug; 7(4):e00496. PubMed ID: 31338197
[TBL] [Abstract][Full Text] [Related]
38. Clinical pharmacokinetics of atenolol--a review.
Kirch W; Görg KG
Eur J Drug Metab Pharmacokinet; 1982; 7(2):81-91. PubMed ID: 6749509
[TBL] [Abstract][Full Text] [Related]
39. Multimorbidity and polypharmacy: which betablocker to use in relation to the pharmacokinetic profile and interaction potential.
Wehling M
Arzneimittelforschung; 2010; 60(2):57-63. PubMed ID: 20329652
[TBL] [Abstract][Full Text] [Related]
40. Influence of cimetidine co-administration on the pharmacokinetics of acebutolol enantiomers and its metabolite diacetolol in a rat model: the effect of gastric pH on double-peak phenomena.
Mostafavi SA; Foster RT
Int J Pharm; 2003 Apr; 255(1-2):81-6. PubMed ID: 12672604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
